SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Josep M. Llovet, Augusto Villanueva, Anja Lachenmayer, Richard S. Finn, Advances in targeted therapies for hepatocellular carcinoma in the genomic era, Nature Reviews Clinical Oncology, 2015, 12, 7, 408

    CrossRef

  2. 2
    Haruhiko Takeda, Hiroki Nishikawa, Yukio Osaki, Kaoru Tsuchiya, Kouji Joko, Chikara Ogawa, Hiroyoshi Taniguchi, Etsuro Orito, Yasushi Uchida, Namiki Izumi, Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan, Liver International, 2015, 35, 5
  3. 3
    Pengfei Zhang, Yu Yang, Feng Wen, Xiaofeng He, Ruilei Tang, Zedong Du, Jing Zhou, Jian Zhang, Qiu Li, Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma, European Journal of Gastroenterology & Hepatology, 2015, 27, 7, 853

    CrossRef

  4. 4
    Guiqi Qin, ChuBiao Zhao, Lili Zhang, Hongyu Liu, Yingyao Quan, Liuying Chai, Shengnan Wu, Xiaoping Wang, Tongsheng Chen, Dihydroartemisinin induces apoptosis preferentially via a Bim-mediated intrinsic pathway in hepatocarcinoma cells, Apoptosis, 2015, 20, 8, 1072

    CrossRef

  5. 5
    Matteo Ruggeri, Andrea Manca, Silvia Coretti, Paola Codella, Valentina Iacopino, Federica Romano, Daniele Mascia, Valentina Orlando, Americo Cicchetti, Investigating the Generalizability of Economic Evaluations Conducted in Italy: A Critical Review, Value in Health, 2015, 18, 5, 709

    CrossRef

  6. 6
    S. Torrecilla, J.M. Llovet, New molecular therapies for hepatocellular carcinoma, Clinics and Research in Hepatology and Gastroenterology, 2015,

    CrossRef

  7. 7
    Massimo Iavarone, Giuseppe Cabibbo, Marco Biolato, Cristina Della Corte, Marcello Maida, Marco Barbara, Michele Basso, Sara Vavassori, Antonio Craxì, Antonio Grieco, Carlo Cammà, Massimo Colombo, Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib, Hepatology, 2015, 62, 3
  8. 8
    Luigi Bolondi, Antonio Craxi, Franco Trevisani, Bruno Daniele, Giovan Giuseppe Di Costanzo, Stefano Fagiuoli, Calogero Cammà, Paolo Bruzzi, Romano Danesi, Federico Spandonaro, Corrado Boni, Armando Santoro, Massimo Colombo, Refining sorafenib therapy: lessons from clinical practice, Future Oncology, 2015, 11, 3, 449

    CrossRef

  9. 9
    Andrea Mancuso, Alessandra Mazzola, Giuseppe Cabibbo, Giovanni Perricone, Marco Enea, Antonio Galvano, Claudio Zavaglia, Luca Belli, Calogero Cammà, Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis, Digestive and Liver Disease, 2015, 47, 4, 324

    CrossRef

  10. 10
    Fabrice Smieliauskas, Chun-Ru Chien, Chan Shen, Daniel M. Geynisman, Ya-Chen Tina Shih, Cost-Effectiveness Analyses of Targeted Oral Anti-Cancer Drugs: A Systematic Review, PharmacoEconomics, 2014, 32, 7, 651

    CrossRef

  11. 11
    Maria Reig, Ferran Torres, Carlos Rodriguez-Lope, Alejandro Forner, Neus LLarch, Jordi Rimola, Anna Darnell, José Ríos, Carmen Ayuso, Jordi Bruix, Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib, Journal of Hepatology, 2014, 61, 2, 318

    CrossRef

  12. 12
    Helge Bruns, Marius Petrulionis, Daniel Schultze, Mohammed Al Saeedi, Shibo Lin, Kenya Yamanaka, Marius Ambrazevičius, Kęstutis Strupas, Peter Schemmer, Glycine inhibits angiogenic signaling in human hepatocellular carcinoma cells, Amino Acids, 2014, 46, 4, 969

    CrossRef

  13. 13
    James G. Orr, Tara Homer, Laura Ternent, Julia Newton, Calum J. McNeil, Mark Hudson, David E.J. Jones, Health related quality of life in people with advanced chronic liver disease, Journal of Hepatology, 2014, 61, 5, 1158

    CrossRef

  14. 14
    Omar Abdel-Rahman, Manal Abdelwahab, Mohammed Shaker, Sherif Abdelwahab, Mohammed Elbassiony, Mahmoud Ellithy, Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience, Journal of the Egyptian National Cancer Institute, 2014, 26, 1, 9

    CrossRef

  15. 15
    Marcus Alexander Wörns, Peter Robert Galle, Sorafenib for the treatment of hepatocellular carcinoma, Hepatic Oncology, 2014, 1, 2, 189

    CrossRef

  16. 16
    Zhi Ven Fong, Kenneth K. Tanabe, The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence-based comparison and review, Cancer, 2014, 120, 18
  17. 17
    Jeroen Dekervel, Jos van Pelt, Chris Verslype, Advanced unresectable hepatocellular carcinoma, Current Opinion in Oncology, 2013, 25, 4, 409

    CrossRef

  18. 18
    Alessandro Cucchetti, Matteo Cescon, Virginia Erroi, Antonio D. Pinna, Cost-effectiveness of liver cancer screening, Best Practice & Research Clinical Gastroenterology, 2013, 27, 6, 961

    CrossRef

  19. 19
    Giuseppe Cabibbo, Marcello Maida, Calogero Cammà, Antonio Craxì, Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?, Expert Review of Anticancer Therapy, 2013, 13, 12, 1355

    CrossRef

  20. 20
    Chiara Genco, Giuseppe Cabibbo, Marcello Maida, Giuseppe Brancatelli, Massimo Galia, Nicola Alessi, Giuseppe Butera, Claudio Genova, Piero Romano, Maurizio Raineri, Antonello Giarratano, Massimo Midiri, Calogero Cammà, Treatment of hepatocellular carcinoma: present and future, Expert Review of Anticancer Therapy, 2013, 13, 4, 469

    CrossRef